Results 291 to 300 of about 545,624 (314)

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing

Annals of Oncology, 2014
Gregory Riely, Marc Ladanyi, M D Hellmann   +2 more
exaly  

Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF

Cancer Cell, 2019
Raúl Rabadan, TERESA Blasco, Francisca Mulero   +2 more
exaly  

Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management

Ca-A Cancer Journal for Clinicians
Kaushal Parikh, Jair Bar, Claudio De Vito   +2 more
exaly  

EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB

Biochemical and Biophysical Research Communications, 2015
Yongsheng Li, Tao Yang, Bo Zhu
exaly  

Treating EGFR‐mutant nonsmall cell lung cancer is no longer a one‐size‐fits‐all approach

Ca-A Cancer Journal for Clinicians
Jyoti Malhotra, Lauren Antrim
exaly  

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment

British Journal of Cancer, 2016
Daoud Sie, Elisabeth Bloemena, P J F Snijders   +2 more
exaly  

Targeting tumor suppressor gene co‐mutations in EGFR ‐mutant nonsmall cell lung cancer: How ACROSS2 sharpens the case for early intensification

Ca-A Cancer Journal for Clinicians
Gilberto de Lima Lopes
exaly  

Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer

Oncogene, 2009
Federico Cappuzzo, Cappuzzo F
exaly  

EGFR

2017
openaire   +1 more source

Aumolertinib with carboplatin–pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open‐label, multicenter, randomized phase 3 study

Ca-A Cancer Journal for Clinicians
Da-Xing Zhu
exaly